Patents Examined by E. C. Ward
-
Process for enhancing the hypocholesterolemic effect of edible pulp and the product obtained thereby
Patent number: 5202122Abstract: Process for enhancing the natural bile acid binding capacity of edible pulp material by either heating an aqueous slurry of the pulp material to at least 40.degree. C. and/or sequentially reacting pulp with a first reactant, such as sodium hydroxide, for activating the pendant hydroxyl groups on the polysaccharide components of the pulp material, a second reactant, such as chloroacetic acid, for carboxylating the activated pendant groups on the polysaccharides, and a third reactant, such as calcium hydroxide, for providing calcium ions which can ionically bond to the carboxylated pendant groups.Type: GrantFiled: April 9, 1991Date of Patent: April 13, 1993Assignee: Humanetics CorporationInventors: Frederic A. Graves, Ani Huang -
Patent number: 5198448Abstract: Method for prophylaxis and treatment of heart diseases using a carbostyril derivative of formula: ##STR1## wherein R.sup.1 is H or CN, and R.sup.2 and R.sup.3 are each H, alkyl optionally substituted by OH, cycloalkyl, alkenyl, phenyl, phenylalkyl having optionally substituents of alkoxyalkoxy, halogen, alkoxy, NO.sub.2, alkyl, CN, alkylthio or alkylsulfinyl on phenyl ring and having optionally OH-substituent on alkyl moiety, phenylsulfonylalkyl having optionally alkoxy substituent on phenyl ring, phenylthioalkyl, phenylsulfinylalkyl having optionally substituents of halogen or alkoxy on phenyl ring, phenoxyalkyl having optionally substituents of halogen or alkoxy on phenyl ring, pyridylalkyl having optionally substituents of halogen or alkoxy on pyridine ring, thienylalkyl, benzoylalkyl, anilinothiocarbonyl, benzoyl, pyridyl, phenylalkenyl, or group of --A-NR.sup.4 R.sup.5 (R.sup.4 and R.sup.Type: GrantFiled: July 24, 1991Date of Patent: March 30, 1993Assignee: Otsuka Pharmaceutical Company, LimitedInventors: Takafumi Fujioka, Shuji Teramoto, Michiaki Tominaga, Yoichi Yabuuchi
-
Patent number: 5198537Abstract: The present invention provides digoxigenin derivatives of the formula: ##STR1## wherein n is a whole number of from 1 to 4 and Z is a carboxyl group or a functional derivative derived therefrom. The present invention also provides digoxigenin conjugates of the general formula: ##STR2## wherein the carrier is an immunogenic carrier material, a nucleic acid or a labelled immunocomponent of a labelled digoxigenin immunoconjugate for use in an immunoassay, m is a number from 1 to the number of coupling positions available on the carrier and Y is the group formed by the reaction of the carboxyl function Z of the digoxigenin derivative of general formula (I) with the reacting position of the carrier material. Also described are uses of these conjugates as nucleic acid probes, immunogens, and in immunoassay.Type: GrantFiled: October 25, 1989Date of Patent: March 30, 1993Assignee: Boehringer Mannheim GmbHInventors: Erasmus Huber, Klaus Muhlegger, Herbert von der Eltz, Bruno Zink
-
Patent number: 5196415Abstract: This invention is in the field of clinical neurology and relates specifically to compounds, compositions and methods for treatment of patients with generalized epilepsy or partial (symptomatic) epilepsy using compounds of the formula: ##STR1## This invention also relates to compounds, compositions and methods of treatment for drug craving in patients addicted to cocaine.Type: GrantFiled: January 29, 1992Date of Patent: March 23, 1993Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: James A. Monn, Andrew Thurkauf, Shunichi Yamaguchi, Michael A. Rogawski, Kenner C. Rice, Mariena V. Mattson, Arthur E. Jacobson
-
Patent number: 5196419Abstract: The invention concerns a heterocyclic cyclic ether of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms;A is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene;X is oxy, thio, sulphinyl, sulphonyl or imino;Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms;R.sup.1 and R.sup.2 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which, together with the oxygen atom to which A.sup.2 is attached and with the carbon atom to which A.sup.3 is attached, defines a ring having 5 to 7 ring atoms, wherein A.sup.2 and A.sup.3 each is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino, and which ring may bear one, two or three substituents; andR.sup.Type: GrantFiled: November 4, 1991Date of Patent: March 23, 1993Assignees: Imperial Chemical Industries PLC, ICI PharmaInventors: Graham C. Crawley, Annie Hamon
-
Patent number: 5196420Abstract: A diketopiperazine compound designated cycloechinulin has been isolated from the sclerotia of the fungi Aspergillus ochraceus. The compound is effective for controlling Coleopteran and Lepidopteran insects.Type: GrantFiled: July 19, 1991Date of Patent: March 23, 1993Assignees: The United States of America as represented by the Secretary of Agriculture, University of Iowa Research Foundation, Biotechnology Research & Development CorporationInventors: Florecita S. deGuzman, Patrick F. Dowd, James B. Gloer, Donald T. Wicklow
-
Patent number: 5194446Abstract: Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.Type: GrantFiled: July 24, 1991Date of Patent: March 16, 1993Assignee: A. H. Robins Company, IncorporatedInventors: Young S. Lo, Joseph C. Nolan, William J. Welstead, Jr., David A. Walsh, Dwight A. Shamblee, Ibrahim M. Uwaydah
-
Patent number: 5194602Abstract: New 9.alpha.-hydroxy-17-methylene steroids are prepared by the introduction of a substituted 17-methylene group in 9.alpha.-hydroxyandrost-4-ene-3, 17-dione.The resulting compounds are useful starting compounds in the synthesis of corticosteroids.Type: GrantFiled: December 12, 1990Date of Patent: March 16, 1993Assignee: Gist-Brocades N.V.Inventors: Jacobus N. M. Batisi, Arthur F. Marx
-
Patent number: 5190952Abstract: A 4-acyloxyquinoline derivative represented by the general formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a C.sub.1 -C.sub.18 alkyl, C.sub.2 -C.sub.18 alkenyl, C.sub.3 -C.sub.10 cycloalkyl which may be optionally substituted, phenylloweralkyl, phenoxyloweralkyl, aryl group, a group OR.sup.4, where R.sup.4 represents a lower alkyl or aryl group, or a group ##STR2## where X represents an oxygen or a sulphur atom; R.sup.2 represents a hydrogen atom, a lower alkyl alkyl group or a group --COOR.sup.5 where R.sup.5 represents a hydrogen atom or a lower alkyl group; R.sup.3 represents a hydrogen atom, a C.sub.1 -C.sub.10 alkyl or C.sub.2 -C.sub.10 alkenyl group, provided that R.sup.1 does not represent OR.sup.4 when R.sup.2 is a hydrogen atom and R.sup.3 is methyl; R.sup.2 and R.sup.3 together represent a group (CH.sub.2).sub.Type: GrantFiled: July 5, 1990Date of Patent: March 2, 1993Assignee: Meiji Seika Kabushiki KaishaInventors: Nobuto Minowa, Tomoya Machinami, Seiji Shibahara, Keiichi Imamura, Michiaki Iwata, Masaru Shimura, Shigeharu Inouye
-
Patent number: 5189025Abstract: Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specfic polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed.Also disclosed are parenteral nutritional formulations which include both citrulline and ornithine which have an arginine concentration of less than about 0.10% by weight final concentration. These formulations inhibiThe government may own certain rights in the present invention pursuant to NCI grant RQI CA3 4-465.Type: GrantFiled: May 14, 1990Date of Patent: February 23, 1993Assignee: Board of Regenets, The University of Texas SystemInventors: Jaffer Ajani, Bruce Grossie, Jr., Kenji Nishioka, David M. Ota
-
Patent number: 5187278Abstract: A novel single-pot trialkylsilyl trifluoromethanesulfonate (R.sub.3 Si-OTf) mediated process produces derivatives of 4-aza 3-keto steroids at the .alpha.-methylenic carbon through electrophilic substitution. These derivatives are useful in the preparation, through elimination of the substituent on the .alpha.-methylene carbon, of .DELTA.-1 olefin 4-aza 3-keto steroids which are potent inhibitors of 5-.alpha. reductase.Type: GrantFiled: November 1, 1991Date of Patent: February 16, 1993Assignee: Merck & Co., Inc.Inventors: Anthony O. King, Kevin Anderson, Sandor Karady, Alan W. Douglas, Newton L. Abramson, Richard F. Shuman
-
Patent number: 5185443Abstract: A process for producing carbamazepine ##STR1## by (i) optionally purifying a solution of CCDA ##STR2## in an anhydrous, aromatic solvent; (ii) if required distilling off water in the solution; (iii) diluting the water-free solution with an additional amount of the anhydrous, aromatic solvent; (iv) in a reactor aminating the diluted solution at from about 70.degree. C. to about 105.degree. C.Type: GrantFiled: July 1, 1991Date of Patent: February 9, 1993Assignee: Arzneimittelwerk Dresden GmbHInventors: Peter Palitzsch, Rainer Muller, Erhard Richter
-
Patent number: 5185346Abstract: (1H-azol-1-ylmethyl)substituted quinoline derivatives, compositions containing the same, and methods of treating mammals suffering from disorders which are characterized by an increase proliferation and/or abnormal differentation of epithelial tissues.Type: GrantFiled: May 23, 1991Date of Patent: February 9, 1993Assignee: Hanssen PharmaceuticaInventors: Gerard C. Sanz, Marc G. Venet, Eddy J. E. Freyne, Alfons H. M. Raeymaekers
-
Patent number: 5183894Abstract: The present invention relates to 2-substituted-1-hydroxyindoles of the following formula: ##STR1## wherein, R.sup.1 is an electron withdrawing group,R.sup.2 is an alkenyl having 2-10 carbon atoms, and N-substituted .alpha.-iminobenzyl group wherein the substituents are selected from the group consisting of phenyl, anilino and dimethylamino, an unsubstituted aromatic group, and an aromatic group having meta or para substituents which are nitro, trifluoromethyl, fluoro, formyl, hydroxyiminomethyl and carbamoyl,R.sup.3 is a halogen atom, andn is 0, 1, or 2,provided that when R.sup.2 is either phenyl or nitro substituted phenyl and n is 0, then R.sup.1 is not cyano.Type: GrantFiled: July 1, 1991Date of Patent: February 2, 1993Assignee: Eastman Kodak CompanyInventors: William R. Schleigh, Thomas R. Welter
-
Patent number: 5182275Abstract: There are disclosed novel compounds of the formula ##STR1## where X is hydrogen, loweralkyl, loweralkoxy, hydroxy, halogen, nitro or trifluoromethyl; R.sub.1 is hydrogen or loweralkyl; R.sub.2 is hydrogen, loweralkyl, arylloweralkyl or --(CH.sub.2).sub.m R.sub.7 wherein m is 1, 2 or 3 and R.sub.7 is cyano or amino; R.sub.3 and R.sub.4 are independently hydrogen or loweralkyl; R.sub.5 and R.sub.6 are independently hydrogen or loweralkyl, or R.sub.5 +R.sub.6 taken together with the carbon atom to which they are attached constitute a cyclobutane, cyclopentane, cyclohexane, cycloheptane, pyrrolidine, piperidine, morpholine or thiomorpholine ring, or R.sub.5 is hydrogen and R.sub.6 is aryl or --CH.sub.2 OR.sub.8 wherein R.sub.8 is hydrogen, loweralkyl or loweralkylcarbonyl, which are useful for enhancing memory.Type: GrantFiled: May 10, 1990Date of Patent: January 26, 1993Assignee: Hoechst-Roussel Pharmaceuticals IncorporatedInventors: Karl Schonafinger, Helen H. Ong
-
Patent number: 5182387Abstract: Novel bis-dibenzoazepine compounds useful in the treatment of malaria and drug-resistant malaria.Type: GrantFiled: October 30, 1991Date of Patent: January 26, 1993Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Jules Freedman, Alan J. Bitonti
-
Patent number: 5182270Abstract: Experiments have been performed which test the stability of thymoxamine in aqueous solution at room temperature and above. It was determined that dimethyl-beta-cyclodextrin slows the hydrolysis degradation of thymoxamine while other beta-cyclodextrin analogs either accelerate the hydrolysis degradation or have no effect on the rate of hydrolysis degradation. Cytological experiments have been performed which show that chemical formulations containing thymoxamine and up to 5% by weight dimethyl-beta-cyclodextrin have the same toxicity as chemical formulations with thymoxamine alone.Type: GrantFiled: August 3, 1989Date of Patent: January 26, 1993Assignee: Iolab CorporationInventors: Donald G. Musson, Orest Olejnik
-
Patent number: 5179085Abstract: N-substituted .alpha.-amino acids and derivatives thereof are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in selectively blocking the N-methyl-D-aspartate (NMDA) excitatory amino acid receptors in mammals and also are useful in treating cerebrovascular disorders such as cerebral ischemia or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus and cerebral trauma as well as for treating schizophrenia, epilepsy, neurodegenerative disorders, Alzheimer's disease or Huntington's disease and also additionally useful as anesthetics in surgical procedures where a finite risk of cerebrovascular damage exists.Type: GrantFiled: April 22, 1991Date of Patent: January 12, 1993Assignee: Warner-Lambert CompanyInventors: Christopher F. Bigge, Graham Johnson
-
Patent number: 5179092Abstract: A compound having the formula (I): ##STR1## wherein A is --CH.sub.2 --, --O--, or --S--; R.sup.1 is CH.sub.3 or OCH.sub.3 ; R.sup.2 is hydroxy or carboxy which may be optionally esterized or amidated; R.sup.3 is H or a lower alkyl; and n is 0 or an integer of 1 to 6 or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 30, 1991Date of Patent: January 12, 1993Assignee: Suntory LimitedInventors: Toshio Tatsuoka, Kenji Suzuki, Fumio Satoh, Seiji Miyano, Kunihiro Sumoto
-
Patent number: 5178880Abstract: Compositions, for the administration of nitrofurantoin to a human or other animal subject, comprising:(a) a safe and effective amount of nitrofurantoin particulates having a surface consisting of nitrofurantoin monohydrate, wherein said particulates have a mean particle size greater than about 200 mesh size;(b) nitrofurantoin monohydrate;(c) an effective amount of a suspending agent; and(d) water;wherein the pH of said composition is from about 1 to about 6; and said nitrofurantoin monohydrate is dissolved in said water at saturation level. The nitrofurantoin of this invention are highly efficacious for the oral delivery of nitrofurantoin.Type: GrantFiled: July 25, 1989Date of Patent: January 12, 1993Assignee: Norwich Eaton Pharmaceuticals, Inc.Inventors: Vijay Shahi, Margaret A. McGowan, Michael J. Kane